Multiple sclerosis: Care needs for 2000 and beyond

Lublin FD , Reingold SC. Defining the clinical course of MS: results of an international study. Neurology 1996; 46: 907–11

Poser CM. New diagnostic criteria for MS—guidelines for research protocols. Ann Neurol 1983; 13: 227–31

Miller DH , Grossman RI , Reingold SC , McFarland HF. The role of magnetic resonance techniques in understanding and managing MS. Brain 1998; 121: 3–24

Johnson J. What can specialist nurses offer in caring for people with MS? In: Thompson AJ , Polman C , Hohfield R , eds. MS—Clinical Challenges and Controversies. London: Dunitz, 1997: 335–43

Thomas S. The role of the specialist nurse in the management of MS. Everyday Neurol 1997; (suppl. 2D)

Robinson T , Hunter M , Neilson S. A Dispatch from the Front Line—the Views of People with MS about their Needs. A Qualitative Approach. A Report for The MS Society. Brunel: MS Research Unit, 1996

Audit Commission. Briefing—A Review of District Nursing Services in England & Wales. London: AC, 1999

Barnes MP. Standards in neurological rehabilitation. Europ J Neurol 1997; 4: 325–31

Nolan M , Nolan J. Rehabilitation in MS: the potential nursing contribution. Br J Nursing 1997; 6: 1292–5

Freeman JA , Langdon DW , Hobart JC , Thompson AJ. The impact of inpatient rehabilitation on progressive MS. Ann Neurol 1997; 42: 236–44

Rossiter DA , Edmondson A , al-Shahi R , Thompson AJ. Integrated care pathways in MS rehabilitation: completing the audit cycle. Multiple Sclerosis 1998; 4: 85–9

Di Fabio RP , Soderberg J , Choi T , Hansen CR , Schapiro RT. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue and functional status for persons with progressive MS. Arch Phys Med Rehab 1998; 79: 141–6

Forbes RB , Lees A , Waugh N , Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive MS. BMJ 1999; 319: 1529–33

Schwartz CE , Coutard-Morris L , Zeng Q. Psychosocial correlates of fatigue in MS. Arch Phys Med Rehab 1996; 77: 165–70

Betts CD , D'Mellow MT , Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in MS. J Neurol Neurosurg Psych 1993; 56: 245–50

Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773–7

Penn RD , Savoy SM , Corcos D Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–21

Vermote R , Ketelaer P , Carlton H. Pain in MS patients. Clin Neurol Neurosurg 1986; 88: 87–93

Rao SM , Leo GJ , Bernardin L , Unverzagt F. Cognitive function in MS—frequency patterns and prediction. Neurology 1991; 41: 685–91

Schiffer RB , Babigian HM. Behavioral disorders in MS, temporal lobe epilepsy and amyotrophic lateral sclerosis. Arch Neurol 1984; 41: 1067–9

Compston DAS. MS: Working party report of the British Society of Rehabilitation Medicine. London: BJRM, 1993

Polman CH , Bertelsmann FW , Loenen AC , Koetsier JC. 4-aminopyridine in treatment of MS patients—long term efficacy and safety. Arch Neurol 1994; S1: 292–6

Rice GPA , Lesaux J , Vandervoort P , Macewan L , Ebers GC. Ondansetron, a 5-HT3 antagonist improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62: 282–4

Freeman J , Johnson J , Rollinson S , Thompson AJ. Standards of Healthcare for People with MS. London: MS Society and Neurorehabilitation and Therapy Services Directorate of the National Hospital for Neurology and Neurosurgery, 1997

Swain SE. MS: Primary health care implications. Nurse Practitioner 1996; 21: 40–50

Holmes J , Madgewick T , Bates D. The cost of MS. Br J Med Econ 1995; 8: 181–93

Walley T , Barton S. A purchaser perspective of managing new drugs; interferon beta as a case study. BMJ 1995; 311: 796–9

Rous E , Coppel A , Hawarth J , Noyce S. A purchaser experience of managing new, expensive drugs; interferon beta. BMJ 1996; 313: 1195–6